Every article, report, and earnings note where VKTX appears.
Vogenx Inc Common Stock is expected to list on NASDAQ on 2026-08-12, but the price range has not been disclosed. The company is a clinical-stage biopharma name focused on metabolic disorders, including post-bariatric hypoglycemia and gastroparesis. The setup favors investors who want an early-stage catalyst story, but shareholders should watch the capital needs and clinical risk closely.
Apnimed, Inc. (NASDAQ: APMD) is expected to list on 2026-07-31 in a $14.00 to $16.00 range, offering 10,000,000 shares. The setup is compelling if investors want a late-stage sleep-apnea catalyst, but the deal still hinges on FDA approval and commercial execution.
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Palatin Technologies, Inc. (NASDAQ: PTN) is expected to list on May 29, 2026, but the price range has not been disclosed. The company is not a traditional IPO: it is a long-public biotech moving to Nasdaq via a resale registration tied to warrant exercises. The bull case is pipeline leverage in obesity and rare disease; the bear case is dilution, losses, and a very tight cash position.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate VKTX ReportCancel anytime